A naturally occurring copper-binding tripeptide with wound healing, anti-aging, and skin regeneration properties.
GHK-Cu (Glycyl-L-Histidyl-L-Lysine copper complex) is a naturally occurring tripeptide that was first isolated from human plasma by Loren Pickart in 1973. It is found in plasma, saliva, and urine at relatively high concentrations in youth, with levels declining significantly with age. This observation contributed to the hypothesis that GHK-Cu plays a role in the regenerative capacity that declines with aging.
The copper(II) complex of GHK demonstrates a remarkable range of biological activities: it promotes wound healing by stimulating collagen and elastin synthesis, attracts immune cells (macrophages, mast cells) to wound sites, acts as an antioxidant, modulates activity of matrix metalloproteinases (collagen-remodeling enzymes), and stimulates glycosaminoglycan synthesis important for skin structure.
GHK-Cu is widely used in topical cosmetic formulations for skin anti-aging, where the evidence for collagen stimulation and skin improvement is reasonably well-supported. Injectable/systemic use for broader anti-aging or healing effects is more experimental — this is where the 'cosmetic' designation transitions into 'research use' territory.
Topical studies demonstrate measurable improvements in skin thickness, elasticity, and reduction of fine lines. Wound healing research in humans and animals shows accelerated closure and improved healing quality. Loren Pickart's decades of work provide a substantial foundation (GHKpeptide.com is a primary research repository).
More recent research (2010s–2020s) has expanded GHK-Cu's profile to include potential gene-regulating effects: genomic studies suggest GHK-Cu affects expression of nearly 4,000 genes, including those involved in inflammation, cancer suppression, pain control, and stem cell maintenance. These findings are compelling but largely based on in vitro genomics studies.
📚 Key Reference: PMID: 25905188 (GHK-Cu skin research), PMID: 25876646 (genomic effects)
Topical use has an excellent safety profile established over decades of cosmetic use. Injectable systemic use is much less characterized — similar cautions as other research peptides apply. Copper toxicity is theoretically possible with excessive systemic dosing, though the doses in clinical contexts are far below copper toxicity thresholds. Consult your provider for injectable use.
GHK-Cu as a topical ingredient: cosmetic use, GRAS status, no FDA drug approval required. Injectable/systemic GHK-Cu: research use, no FDA approval, available through compounding pharmacies. The topical-to-injectable distinction is important — very different regulatory frameworks.